Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Oct 25, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping patients who come to the Emergency Department with high blood sugar (hyperglycemia) to better understand and manage their risk of developing Type 2 Diabetes. The researchers want to find out if providing patients with educational materials about diabetes can improve their knowledge and encourage them to adopt healthier habits. They will ask participants to fill out a survey when they visit the Emergency Department and again two weeks later to see if their understanding and behaviors have changed.
To be eligible for this study, participants must be at least 18 years old and have a blood sugar level of 200 mg/dL or higher when they visit the Emergency Department. This applies to both those who already have a diagnosis of Type 2 Diabetes and those who do not. All participants will receive standard emergency care along with an educational packet designed to help them learn more about diabetes. This trial is currently recruiting patients, and all genders are welcome to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Persons 18 years of age or older who present as patients in the Robert Wood Johnson University Hospital Emergency Department with or without a preexisting Type 2 Diabetes Mellitus diagnosis with a blood glucose of ≥200 mg/dL. Participants must speak English to participate in the study.
- Exclusion Criteria:
- • Age less than 18 years and blood glucose \<200 mg/dL.
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Brunswick, New Jersey, United States
Patients applied
Trial Officials
Sara Heinert, PhD, MPH
Principal Investigator
Rutgers Robert Wood Johnson Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported